JAK-STAT Pathway-Associated Skin Diseases: A Refined Functional Framework for Inflammatory Skin Diseases

    June 2026 in “ Frontiers in Immunology ”
    Bingrun Li, Xiaoting Song, Cunhao Shan … Litao Zhang
    Studysummary This review highlights the potential for JAK inhibitors to effectively treat inflammatory and autoimmune skin diseases by targeting the JAK-STAT signaling pathway, advocating for an integrated approach to enhance targeted therapy.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on frontiersin.org →
    Discuss this study in the Community →

    Research cited in this study 24

    1. Sustaining Treatment Response in Alopecia Areata Through Tofacitinib Dose Tapering: A Single-Center Retrospective Study Journal of the American Academy of Dermatology · 2025
    2. Alopecia Areata Nature Reviews Disease Primers · 2025
    3. Effectiveness and Safety of Baricitinib in Severe Alopecia Areata: 48-Week Results Journal of the European Academy of Dermatology and Venereology · 2025
    4. Successful Treatment of Severe Diffuse Alopecia Areata with Abrocitinib Anais Brasileiros de Dermatologia · 2025
    5. Long-Term Safety and Efficacy of Ritlecitinib in Adults and Adolescents with Alopecia Areata and at Least 25% Scalp Hair Loss: Results from the ALLEGRO-LT Phase 3, Open-Label Study Journal of the European Academy of Dermatology and Venereology · 2025
    6. Oral Abrocitinib for Treatment of Refractory Alopecia Areata: A Retrospective Study Journal of the American Academy of Dermatology · 2024
    7. Efficacy and Safety of the Oral Janus Kinase 3/Tyrosine Kinase Inhibitor Ritlecitinib Over 24 Months: Integrated Analysis of the ALLEGRO Phase IIb/III and Long-Term Phase III Clinical Studies in Alopecia Areata British Journal of Dermatology · 2024
    8. Sustained Hair Regrowth With Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Trial Journal of the American Academy of Dermatology · 2024
    9. Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata JAMA Dermatology · 2024
    10. Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up Journal of asthma and allergy · 2024
    11. Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2 Journal of the European Academy of Dermatology and Venereology · 2024
    12. Ritlecitinib: First Approval Drugs · 2023
    13. New Small Molecules in Dermatology: For Autoimmunity, Inflammation, and Beyond Inflammation Research · 2023
    14. Baricitinib for the Treatment of Alopecia Areata Drugs · 2023
    15. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    16. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials American Journal of Clinical Dermatology · 2023
    17. Treatment of Alopecia Areata With the Janus Kinase Inhibitor Upadacitinib: A Retrospective Cohort Study Journal of the American Academy of Dermatology · 2023
    18. A Case of Atopic Dermatitis with Alopecia Universalis in a Patient Treated with Abrocitinib JAAD case reports · 2022
    19. The JAK/STAT Signaling Pathway: From Bench to Clinic Signal Transduction and Targeted Therapy · 2021
    20. Resident Memory T Cells in Autoimmune Skin Diseases Frontiers in immunology · 2021
    21. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    22. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study Dermatology · 2018
    23. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis Journal of Investigative Dermatology · 2018
    24. Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016